BACKGROUND: Formation of advanced glycation end-products (AGEs) is a major problem in uremic patients treated with peritoneal dialysis (PD). Application of additives with known anti-glycosylation properties to PD fluid may be beneficial in minimizing the formation of AGEs. This study aimed to evaluate the effect of carnosine and its related peptides homocarnosine and anserine against the formation of AGEs in PD fluid. METHODS: PD solutions (1.5% dextrose) were incubated with human serum albumin (HSA) or collagen (type IV) with or without 10 mmol/L of each of carnosine, anserine, homocarnosine, histidine, and aminoguanidine. The formation of AGEs was followed by fluorescence spectrophotometry at weekly intervals for 7 weeks. For the determination of the acute effect of carnosine and related compounds, HSA and collagen were incubated with 4.25% dextrose PD solutions for 24 hours, followed by incubation with 20 mmol/L of carnosine and related compounds for another 24 hours. The rate of AGE formation was monitored by fluorescence spectrophotometry. RESULTS: Carnosine and related compounds showed effective regression in AGE formation in both types of proteins in both long- and short-term exposure to PD fluids at a rate of effectiveness of the order of carnosine > homocarnosine > anserine, aminoguanidine > histidine in long-term exposure, and homocarnosine > carnosine > aminoguanidine > anserine > histidine in short-term exposure. CONCLUSION: Carnosine and related peptides could suppress the formation of AGEs initiated by PD fluid. This observation may provide a new therapeutic approach for the prevention and treatment of the AGE-related complications in PD patients.
BACKGROUND: Formation of advanced glycation end-products (AGEs) is a major problem in uremicpatients treated with peritoneal dialysis (PD). Application of additives with known anti-glycosylation properties to PD fluid may be beneficial in minimizing the formation of AGEs. This study aimed to evaluate the effect of carnosine and its related peptides homocarnosine and anserine against the formation of AGEs in PD fluid. METHODS:PD solutions (1.5% dextrose) were incubated with human serum albumin (HSA) or collagen (type IV) with or without 10 mmol/L of each of carnosine, anserine, homocarnosine, histidine, and aminoguanidine. The formation of AGEs was followed by fluorescence spectrophotometry at weekly intervals for 7 weeks. For the determination of the acute effect of carnosine and related compounds, HSA and collagen were incubated with 4.25% dextrosePD solutions for 24 hours, followed by incubation with 20 mmol/L of carnosine and related compounds for another 24 hours. The rate of AGE formation was monitored by fluorescence spectrophotometry. RESULTS: Carnosine and related compounds showed effective regression in AGE formation in both types of proteins in both long- and short-term exposure to PD fluids at a rate of effectiveness of the order of carnosine > homocarnosine > anserine, aminoguanidine > histidine in long-term exposure, and homocarnosine > carnosine > aminoguanidine > anserine > histidine in short-term exposure. CONCLUSION: Carnosine and related peptides could suppress the formation of AGEs initiated by PD fluid. This observation may provide a new therapeutic approach for the prevention and treatment of the AGE-related complications in PDpatients.
Authors: Felix Schmöhl; Verena Peters; Claus Peter Schmitt; Gernot Poschet; Michael Büttner; Xiaogang Li; Tim Weigand; Tanja Poth; Nadine Volk; Jakob Morgenstern; Thomas Fleming; Peter P Nawroth; Jens Kroll Journal: Cell Mol Life Sci Date: 2019-05-09 Impact factor: 9.261
Authors: Lisienny C T Rempel; Alessandra B Finco; Rayana A P Maciel; Bruna Bosquetti; Larissa M Alvarenga; Wesley M Souza; Roberto Pecoits-Filho; Andréa E M Stinghen Journal: Toxins (Basel) Date: 2015-05-14 Impact factor: 4.546
Authors: Verena Peters; Celine Q F Klessens; Hans J Baelde; Benjamin Singler; Kimberley A M Veraar; Ana Zutinic; Jakub Drozak; Johannes Zschocke; Claus P Schmitt; Emile de Heer Journal: Amino Acids Date: 2015-07-24 Impact factor: 3.520
Authors: Alan R Hipkiss; Stephanie P Cartwright; Clare Bromley; Stephane R Gross; Roslyn M Bill Journal: Chem Cent J Date: 2013-02-25 Impact factor: 4.215
Authors: Estifanos Baye; Kirthi Menon; Maximilian Pj de Courten; Arul Earnest; James Cameron; Barbora de Courten Journal: BMJ Open Date: 2017-09-01 Impact factor: 2.692